NCT03196830CompletedPhase 2
CAR-T for R/R B-NHL
Safety and Efficacy of Chimeric Antigen Receptor T Cell (CAR-T) Treating Relaspe/Refractory CD19/CD20/CD22/CD30 Postive Non-Hodgkin Lymphoma
Source: ClinicalTrials.gov · Last updated 3 Jun 2026
Brief summary (registry, in English)
This study is a single arm study to investigate the efficacy and safety of CAR-T targeted CD19/CD20/CD22/CD30 in relapse and refractory non-Hodgkin lymphoma patients. Ten patients will recruieted, admitted in hospital for 1 month for the CAR-T treatment and follow-up for at least 2 years.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 168 (actual)
- First submitted
- 20 Jun 2017
- Start date
- 1 Jun 2017
- Primary completion date
- 31 Jan 2024
- Lead sponsor
- The First Affiliated Hospital of Soochow University
- Diseases
- Childhood cancers
- NCT number
- NCT03196830
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 168
- From 1 Jun 2017 to the primary completion date, 31 Jan 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received immunol suppression treatment or steroids in recent 1 week before recruitment
Other illness
- Uncontrolled infection
- HIV positive patients
- Active HBV or HCV infection
- Uncured malignancies other than non-Hodgkin lymphoma
- Severe heart disease
Other
- Women in pregnancy and lactation
- Refuse to conception control during treatment and 1 year after CAR-T infusion
- Have participated similar trial for treating relapse/refractory non-Hodgkin lymphoma
- Inheritated immune deficiancy
Who the study is looking for
- Histological detection confirmed CD19/CD20/CD22/CD30 postive non-Hodgkin lymphoma
- Recieved more than 2 lines of chemotherapy
- With contraindications of hematopoietic stem cell transplantation or relapse after hematopoietic stem cell transplantation
- Expected survival more than 3 months
- Karmofsky performance score ≤ 60, and ECOG ≥ 2.
- Enough organ function: EF≥50%; normal ECG; CCR≥40ml/min; ALT and AST ≤ 3 × upper limitation of normal, T-BIL ≤ 2.0mg/dl; PT and APTT \< 2 × upper limitation of normal; SpO2 \> 92%
- CBC results: Hb ≥ 80g/L, ANC \> 1 × 10E9/L, Plt ≥ 50 × 10E9/L
- Results of pregnant test should be negative, and agree to conception control during treatment and 1 year after CAR-T infusion
- With measurable disease
- Written informed consent could be acquired
Age in the registry: 6 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Soochow University Coordinator of this site? Confirm its status | Suzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.